Dendreon jumps on 'heavyweight' board appointments

Few vaccine companies get a big bump in their stock prices when they add members to their boards. But you don't often get "heavyweight gunslingers" like these. Dendreon, which is nearing an NDA for Provenge, announced that Genentech CEO Ian Clark and Pedro Granadillo, who had been Eli Lilly's top manufacturing aficionado, are coming on board. And investors bid up their shares by eight percent. Dendreon release | Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.